Sucampo Pharmaceuticals Inc (SCMP)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

805 KING FARM BOULEVARD, SUITE 550 ROCKVILLE, MD 20850

Sucampo Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs based on prostones. It develops prostones for the treatment of gastrointestinal, respiratory, vascular, and central nervous system diseases and disorders. The company's principal product includes AMITIZA, which is used for the treatment of chronic idiopathic constipation in adults and is approved by FDA for use by adults primarily in the United States. Sucampo Pharmaceuticals is also conducting two pivotal Phase III clinical trials of AMITIZA for the treatment of irritable bowel syndrome with constipation. Its additional compounds in development include SPI-8811, used for the treatment of ulcers induced by nonsteroidal anti-inflammatory drugs (NSAID), portal hypertension, nonalcoholic fatty liver disease, cystic fibrosis, and chronic obstructive pulmonary disease; and SPI-017, used for the treatment of peripheral arterial and vascular disease, and central nervous system disorders. The company has completed Phase I trials of SPI-8811 for NSAID-induced ulcers; a Phase IIa trial for nonalcoholic fatty liver disease; and a Phase IIa trial for cystic fibrosis. It is also developing an oral formulation of SPI-017 for the treatment of Alzheimer's disease. In addition, the company plans to begin Phase II/III pivotal clinical trials of AMITIZA for the treatment of opioid-induced bowel dysfunction. Sucampo Pharmaceuticals has a collaboration and license agreement with Takeda Pharmaceutical Company Limited to jointly develop and commercialize AMITIZA for chronic idiopathic constipation, irritable bowel syndrome with constipation, opioid-induced bowel dysfunction, and other gastrointestinal indications in the United States and Canada. The company was founded by Sachiko Kuno and Ryuji Ueno in 1996.

View SEC Filings from SCMP instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding SCMP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SCMP BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

UENO RYUJI

  • 10% Owner
No longer subject to file 2018-02-13 0

KUNO SACHIKO

  • 10% Owner
No longer subject to file 2018-02-13 0

OCONNELL MAUREEN

  • Director
No longer subject to file 2018-02-13 0

GREENLEAF PETER CHIEF EXECUTIVE OFFICER

  • Officer
No longer subject to file 2018-02-13 0

JOHNSON JOHN

  • Director
No longer subject to file 2018-02-13 0

SPIEGEL ROBERT J.

  • Director
No longer subject to file 2018-02-13 0

KIENER PETER A CHIEF SCIENCE OFFICER

  • Officer
No longer subject to file 2018-02-13 0

LICHTLEN PETER CHIEF MEDICAL OFFICER

  • Officer
No longer subject to file 2018-02-13 0

DONLEY MATTHEW MAXWELL EVP, GLOBAL HR, IT & STRATEGY

  • Officer
No longer subject to file 2018-02-13 0

WALBERT TIMOTHY P

  • Director
No longer subject to file 2018-02-13 0

EDICK PAUL R

  • Director
No longer subject to file 2018-02-13 0

PFREUNDSCHUH PETER P. CFO

  • Officer
No longer subject to file 2018-02-13 0

DRIGGS ALEX GENERAL COUNSEL & CORP. SEC.

  • Officer
No longer subject to file 2018-02-13 0

MEYENBURG JASON PATRICK CHIEF COMMERCIAL OFFICER

  • Officer
No longer subject to file 2018-02-13 0

BRYAN JONES W. SR. VICE PRES., BD & LICENSING

  • Officer
No longer subject to file 2018-02-13 0

SMITH KAREN L.

  • Director
No longer subject to file 2018-02-13 0

ALDER MATTHIAS EVP, GEN. COUNCIL & SEC.

  • Officer
No longer subject to file 2017-06-30 0

SMITH ANDREW P CHIEF FINANCIAL OFFICER

  • Officer
491 2016-12-31 0

S&R TECHNOLOGY HOLDINGS, LLC

  • FORMER 10% OWNER
No longer subject to file 2016-12-19 0

GETMAN DANIEL P

  • Director
0 2016-11-28 0

KNAPP THOMAS J

  • FORMER OFFICER
No longer subject to file 2015-07-20 0

MIELE STANLEY G CHIEF COMMERCIAL OFFICER

  • Officer
93 2015-06-30 0

MUNDER BARBARA A

  • Director
0 2015-05-29 0

TOLLIVER KEI S

  • Director
0 2015-05-29 0

CELESTE ANTHONY C.

  • Director
68,800 2015-03-11 0

ASHTON WILLIAM

  • Director
0 2015-03-11 0

CLAIBORNE CARY J

  • FORMER CHIEF FINANCIAL OFFICER
No longer subject to file 2014-12-15 0

DOLECEK GAYLE R

  • Director
0 2014-03-18 0

MAUDLIN TIMOTHY I

  • Director
No longer subject to file 2013-05-15 0

NANTAHALA CAPITAL MANAGEMENT, LLC

  • 10% Owner
No longer subject to file 2012-04-23 0

FERRARA ANDREW J

  • Director
0 2011-05-02 0

EGAN JAMES

  • Director
0 2011-05-02 0

SMILEK JAN CHIEF ACCOUNTING OFFICER

  • Officer
0 2009-01-15 0

WRIGHT JOHN C

  • Director
1,000 2008-02-19 0

MINE HIDETOSHI

  • Director
  • 10% Owner
1,984,196 2007-12-31 0

ORIX CORP

  • 10% Owner
1,981,712 2007-08-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments